Compugen to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Compugen (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company specializing in AI/ML-powered computational target discovery, has announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference. The company's management will engage in a fireside chat that will be accessible on-demand through Compugen's website starting September 5, 2025, at 7:00 AM ET. The presentation will remain available for 90 days on the company's Investor Relations section.
Compugen (NASDAQ: CGEN), societ脿 in fase clinica specializzata in immunoterapia oncologica e nella scoperta di target tramite AI/ML, ha annunciato la sua partecipazione al H.C. Wainwright 27th Annual Global Investment Conference. Il management terr脿 un fireside chat che sar脿 disponibile on-demand sul sito di Compugen a partire dal 5 settembre 2025 alle 7:00 ET. La presentazione rester脿 accessibile per 90 giorni nella sezione Investor Relations della societ脿.
Compugen (NASDAQ: CGEN), una compa帽铆a en fase cl铆nica dedicada a la inmunoterapia contra el c谩ncer y al descubrimiento de dianas mediante AI/ML, ha anunciado su participaci贸n en la H.C. Wainwright 27th Annual Global Investment Conference. La direcci贸n ofrecer谩 un fireside chat que estar谩 disponible on-demand en la web de Compugen desde el 5 de septiembre de 2025 a las 7:00 ET. La presentaci贸n quedar谩 online durante 90 d铆as en la secci贸n de Investor Relations de la compa帽铆a.
Compugen (NASDAQ: CGEN), AI/ML 旮半皹 瓿勳偘鞝� 響滌爜 氚滉荡鞚� 鞝勲鞙茧 頃橂姅 鞛勳儊 雼硠 鞎� 氅挫棴旃橂 須岇偓臧� H.C. Wainwright 27th Annual Global Investment Conference鞐� 彀胳棳頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. 瓴届榿歆勳潃 fireside chat鞐� 彀胳棳頃橂┌ 頃措嫻 鞓侅儊鞚� 2025雲� 9鞗� 5鞚� 鞓れ爠 7:00 ET攵�韯� Compugen 鞗轨偓鞚错姼鞐愳劀 鞓敂毵摐搿� 鞝滉车霅╇媹雼�. 氚滍憸 鞛愲電� 須岇偓鞚� 韴瀽鞛� 甏�瓿�(Investor Relations) 靹轨厴鞐� 90鞚缄皠 瓴岇灛霅� 鞓堨爼鞛呺媹雼�.
Compugen (NASDAQ: CGEN), soci茅t茅 en phase clinique sp茅cialis茅e dans l'immunoth茅rapie du cancer et la d茅couverte de cibles par IA/ML, a annonc茅 sa participation 脿 la H.C. Wainwright 27th Annual Global Investment Conference. La direction tiendra un fireside chat qui sera disponible 脿 la demande sur le site de Compugen 脿 partir du 5 septembre 2025 脿 7h00 ET. La pr茅sentation restera accessible pendant 90 jours dans la rubrique Investor Relations de la soci茅t茅.
Compugen (NASDAQ: CGEN), ein in der klinischen Phase befindliches Unternehmen f眉r Krebsimmuntherapie, das sich auf KI/ML-gest眉tzte Zielidentifikation spezialisiert hat, k眉ndigt seine Teilnahme an der H.C. Wainwright 27th Annual Global Investment Conference an. Das Management wird an einem Fireside-Chat teilnehmen, der ab dem 5. September 2025 um 7:00 Uhr ET on-demand auf der Compugen-Website abrufbar sein wird. Die Pr盲sentation bleibt f眉r 90 Tage im Investor-Relations-Bereich des Unternehmens verf眉gbar.
- None.
- None.
HOLON,
The fireside chat will be available on demand on the Investor Relations section of Compugen's 听补迟 聽from Friday, September 5, 2025, 7:00 AM ET聽for 90 days.
础产辞耻迟听颁辞尘辫耻驳别苍
Compugen聽is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive AI/ML powered computational discovery platform (Unigen鈩�) to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has two proprietary product candidates in Phase 1 development: COM701, a potential first-in-class anti-PVRIG antibody and COM902,聽a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies.聽GS-0321 (previously COM503), a potential first-in-class, high affinity anti-IL-18 binding protein antibody, which is in Phase 1 development is licensed to Gilead. In addition, the Company's therapeutic pipeline of early-stage聽immuno-oncology programs consists of research programs aiming to address new mechanisms to activate the immune system against cancer. Compugen聽is headquartered in
Company contact:
Yvonne Naughton, Ph.D.
Vice President, Head of Investor Relations and Corporate Communications
贰尘补颈濒:听[email protected]
Tel: +1聽(628)聽241-0071聽
View original content:
SOURCE Compugen Ltd.
FAQ
When is Compugen's (CGEN) presentation at the H.C. Wainwright Conference?
How long will Compugen's (CGEN) H.C. Wainwright Conference presentation be available?
Where can I watch Compugen's (CGEN) H.C. Wainwright Conference presentation?
What type of company is Compugen (CGEN)?
